Abstract
The protein tyrosine phosphatase PTP1B, previously recognized for its role in downregulating insulin and leptin signaling, has now been shown to function as a positive regulator of signaling events associated with breast tumorigenesis. Inhibitors of PTP1B that have been developed as drug candidates for treatment of diabetes and obesity may offer new avenues for the treatment of breast cancer.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Apoptosis
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism*
-
Cell Proliferation
-
Cell Transformation, Neoplastic
-
Female
-
Humans
-
Mice
-
Mice, Knockout
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1
-
Protein Tyrosine Phosphatases / antagonists & inhibitors
-
Protein Tyrosine Phosphatases / physiology*
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-2 / physiology
-
Signal Transduction
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Receptor, ErbB-2
-
PTPN1 protein, human
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1
-
Protein Tyrosine Phosphatases
-
Ptpn1 protein, mouse
-
Trastuzumab